{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Proportion of participants who survived without disease progression at 2 years","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\ncyclophosphamide: Given IV\n\ndoxorubicin hydrochloride: Given IV\n\nvincristine sulfate: Given IV\n\nprednisone: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Arm I (CHOP)"},{"description":"Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nlomustine: Given PO\n\netoposide: Given PO\n\ncyclophosphamide: Given PO\n\nprocarbazine hydrochloride: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Arm II (Oral Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Participants whose disease and survival status were known at 2 years","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"proportion"}